Isoniazid | The Medical Letter Inc.

Matching articles for "Isoniazid"

In Brief: A Shorter Treatment Regimen for Tuberculosis (online only)

The Medical Letter on Drugs and Therapeutics • August 23, 2021; (Issue 1631)

In a clinical trial conducted by the CDC's Tuberculosis Trials Consortium in collaboration with the NIH-funded AIDS Clinical Trials Group, a new 4-month regimen for treatment of drug-susceptible pulmonary...

Med Lett Drugs Ther. 2021 Aug 23;63(1631):e3 | Show Full Introduction Hide Full Introduction

In Brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 Vaccines (online only)

The Medical Letter on Drugs and Therapeutics • July 26, 2021; (Issue 1629)

On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) about an increased risk of myocarditis...

On June 25, 2021, the FDA added a warning to the Fact Sheets for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) about an increased risk of myocarditis and pericarditis following administration of the vaccines.

Med Lett Drugs Ther. 2021 Jul 26;63(1629):e9 | Show Full Introduction Hide Full Introduction

Drugs for Osteoarthritis

The Medical Letter on Drugs and Therapeutics • September 1, 2014; (Issue 1450)

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight...

Many different drugs are used for treatment of osteoarthritis pain, but none of them prevent progression of the disease. Many nonpharmacologic approaches are available as well, including weight management, exercise, physical therapy, assistive devices, and total joint arthroplasty. New guidelines for the management of osteoarthritis have recently been published.

Med Lett Drugs Ther. 2014 Sep 1;56(1450):80-4 | Show Full Introduction Hide Full Introduction

Two New Drugs for Skin and Skin Structure Infections

The Medical Letter on Drugs and Therapeutics • August 18, 2014; (Issue 1449)

The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a...

The FDA has approved two new drugs for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Dalbavancin (Dalvance – Durata) is a long-acting intravenous (IV) lipoglycopeptide antibiotic similar to telavancin (Vibativ). Tedizolid phosphate (Sivextro – Cubist) is an IV and oral oxazolidinone antibacterial drug similar to linezolid (Zyvox). A third IV antibiotic, oritavancin (Orbactiv), recently approved by the FDA for the same indication, will be reviewed in a future issue.

Med Lett Drugs Ther. 2014 Aug 18;56(1449):73-5 | Show Full Introduction Hide Full Introduction

Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis

The Medical Letter on Drugs and Therapeutics • August 19, 2013; (Issue 1423)

Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of...

Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB). It is the first drug approved specifically to treat MDR-TB.

Med Lett Drugs Ther. 2013 Aug 19;55(1423):66-8 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • April 1, 2012; (Issue 116)

Tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses challenges to its treatment and control. Guidelines with detailed management recommendations are available from the American Thoracic Society, Centers for Disease Control and Prevention (CDC) and Infectious Diseases Society of America (IDSA).

Treat Guidel Med Lett. 2012 Apr;10(116):29-36 | Show Full Introduction Hide Full Introduction

New Simvastatin Dosing Recommendations

The Medical Letter on Drugs and Therapeutics • August 8, 2011; (Issue 1370)

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).

Med Lett Drugs Ther. 2011 Aug 8;53(1370):61-2 | Show Full Introduction Hide Full Introduction

Drugs for Bacterial Infections

The Medical Letter on Drugs and Therapeutics • June 1, 2010; (Issue 94)

The text below reviews some common bacterial infections and their treatment. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter...

Treat Guidel Med Lett. 2010 Jun;8(94):43-52 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • October 1, 2009; (Issue 86)

Even though the incidence continues to decline in the United States, tuberculosis (TB) is still a common cause of death worldwide, and the prevalence of drug-resistant TB poses severe challenges to its treatment and control. Guidelines with detailed management recommendations are available from the Centers for Disease Control and Prevention (CDC), American Thoracic Society and Infectious Diseases Society of America (IDSA).

Treat Guidel Med Lett. 2009 Oct;7(86):75-82 | Show Full Introduction Hide Full Introduction

Drugs That May Cause Psychiatric Symptoms

The Medical Letter on Drugs and Therapeutics • December 15, 2008; (Issue 1301)

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment could also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Click here to view the free full article.

Med Lett Drugs Ther. 2008 Dec 15;50(1301):100-3 | Show Full Introduction Hide Full Introduction

Drug Interactions with Simvastatin

The Medical Letter on Drugs and Therapeutics • October 20, 2008; (Issue 1297)

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became...

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.

Med Lett Drugs Ther. 2008 Oct 20;50(1297):83-4 | Show Full Introduction Hide Full Introduction

Choice of Antibacterial Drugs

The Medical Letter on Drugs and Therapeutics • May 1, 2007; (Issue 57)

Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.

Treat Guidel Med Lett. 2007 May;5(57):33-50 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • March 1, 2007; (Issue 55)

Even though the incidence continues to decline, tuberculosis (TB) is still a problem in the United States. Treatment of TB can be divided into treatment of latent infection and treatment of active disease. Atable listing the first-line drugs used for treatment of TB with their doses and adverse effects can be found on page 16. Other guidelines with more detailed management recommendations are available.

Treat Guidel Med Lett. 2007 Mar;5(55):15-22 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • December 1, 2004; (Issue 28)

Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).

Treat Guidel Med Lett. 2004 Dec;2(28):83-2 | Show Full Introduction Hide Full Introduction

Choice of Antibacterial Drugs

The Medical Letter on Drugs and Therapeutics • March 1, 2004; (Issue 19)

New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.

Treat Guidel Med Lett. 2004 Mar;2(19):13-22 | Show Full Introduction Hide Full Introduction

Which SSRI?

The Medical Letter on Drugs and Therapeutics • November 24, 2003; (Issue 1170)

Five different selective serotonin reuptake inhibitors (SSRIs) are promoted for treatment of depression and a sixth (fluvoxamine) for use in obsessive compulsive disorder. Which one should we prescribe for our...

Med Lett Drugs Ther. 2003 Nov 24;45(1170):93-5 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.

Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 | Show Full Introduction Hide Full Introduction

Drugs That May Cause Psychiatric Symptoms

The Medical Letter on Drugs and Therapeutics • July 8, 2002; (Issue 1134)

Many drugs can cause psychiatric symptoms, but a causal connection is often difficult to establish. Psychiatric symptoms that emerge during drug treatment may also be due to the underlying illness, previously unrecognized psychopathology, or psychosocial factors. The withdrawal of some drugs can cause symptoms such as anxiety, psychosis, delirium, agitation or depression.

Med Lett Drugs Ther. 2002 Jul 8;44(1134):59-62 | Show Full Introduction Hide Full Introduction

Rifapentine--A Long-Acting Rifamycin for Tuberculosis

The Medical Letter on Drugs and Therapeutics • February 26, 1999; (Issue 1047)

Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary...

Rifapentine, a long-acting analog of rifampin developed in the 1960's, has received an accelerated approval from the FDA for oral use, with at least one other drug, in the treatment of pulmonary tuberculosis.

Med Lett Drugs Ther. 1999 Feb 26;41(1047):21-2 | Show Full Introduction Hide Full Introduction

Systemic Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • September 12, 1997; (Issue 1009)

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.

Med Lett Drugs Ther. 1997 Sep 12;39(1009):86-8 | Show Full Introduction Hide Full Introduction

Itraconazole for Onychomycosis

The Medical Letter on Drugs and Therapeutics • January 19, 1996; (Issue 966)

Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.

Med Lett Drugs Ther. 1996 Jan 19;38(966):5-6 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated Infections

The Medical Letter on Drugs and Therapeutics • October 13, 1995; (Issue 959)

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with...

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.

Med Lett Drugs Ther. 1995 Oct 13;37(959):87-94 | Show Full Introduction Hide Full Introduction

Drugs For Tuberculosis

The Medical Letter on Drugs and Therapeutics • August 4, 1995; (Issue 954)

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).

Med Lett Drugs Ther. 1995 Aug 4;37(954):67-70 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • October 29, 1993; (Issue 908)

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).

Med Lett Drugs Ther. 1993 Oct 29;35(908):99-102 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated infections

The Medical Letter on Drugs and Therapeutics • September 3, 1993; (Issue 904)

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with...

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.

Med Lett Drugs Ther. 1993 Sep 3;35(904):79-86 | Show Full Introduction Hide Full Introduction

Itraconazole

The Medical Letter on Drugs and Therapeutics • January 22, 1993; (Issue 888)

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses...

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses occur both in normal hosts and in immunocompromised patients, such as those with AIDS (RW Bradsher, Clin Infect Dis, 14:S82, 1992; LJ Wheat, Clin Infect Dis, 14:S91, 1992).

Med Lett Drugs Ther. 1993 Jan 22;35(888):7-9 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • February 7, 1992; (Issue 863)

After many years of decline in the USA, the incidence of tuberculosis (TB) has recently increased, partly because the disease occurs more frequently in patients with human immunodeficiency virus (HIV) infection and in the homeless (PF Barnes et al, N Engl J Med, 324:1644, 1991; Morbid Mortal Weekly Rep, 40:869, Dec 20, 1991).

Med Lett Drugs Ther. 1992 Feb 7;34(863):10-2 | Show Full Introduction Hide Full Introduction

Drugs For AIDS And Associated Infections

The Medical Letter on Drugs and Therapeutics • October 18, 1991; (Issue 855)

A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in...

Med Lett Drugs Ther. 1991 Oct 18;33(855):95-102 | Show Full Introduction Hide Full Introduction

Foods Interacting With MAO Inhibitors

The Medical Letter on Drugs and Therapeutics • February 10, 1989; (Issue 785)

Many fermented foods contain tyramine as a byproduct formed by the bacterial breakdown of the amino acid tyrosine; it can also be formed by para-hydroxylation of phenylethylamine or dehydroxylation of DOPA and dopamine. Tyramine and some other amines found in food can cause hypertensive reactions in patients taking monoamine oxidase (MAO)inhibitors.

Med Lett Drugs Ther. 1989 Feb 10;31(785):11-2 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • April 8, 1988; (Issue 763)

After many years of decline, the incidence of tuberculosis has recently increased because the disease occurs in patients with AIDS (Morbid Mortal Weekly Rep, 36:817, Jan 1, 1988). For uncomplicated tuberculosis, the recent trend in tuberculosis treatment has been toward a shorter period of therapy and increased use of pyrazinamide.

Med Lett Drugs Ther. 1988 Apr 8;30(763):43-4 | Show Full Introduction Hide Full Introduction

Drugs For Treatment of Deep Fungal Infections

The Medical Letter on Drugs and Therapeutics • March 11, 1988; (Issue 761)

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care...

The incidence of opportunistic deep fungal infections continues to increase, particularly among patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units.

Med Lett Drugs Ther. 1988 Mar 11;30(761):30-2 | Show Full Introduction Hide Full Introduction